136
Participants
Start Date
January 9, 2020
Primary Completion Date
September 11, 2023
Study Completion Date
June 26, 2024
Alpha-1 antitrypsin (AAT)
AAT is a lyophilized product for intravenous administration
Placebo
Albumin solution administered intravenously
MSKCC, New York
Johns Hopkins Hospital, Baltimore
Virginia Commonwealth Univ., Richmond
Duke, Durham
Levine Cancer Center, Charlotte
Northside Hospital, Atlanta
University of Florida, Gainesville
Moffitt Cancer Center, Tampa
Vanderbilt-Ingram Cancer Center, Nashville
Ohio State Univ.Medical Center, Columbus
Cleveland Clinic, Cleveland
IU Hospital, Indianapolis
Karmanos Cancer Center, Detroit
Medical College of Wisconsin, Milwaukee
University of Wisconsin, Madison
University of Minnesota, Minneapolis
Washington University, St Louis
Univ. of Kansas Cancer Center, Westwood
Center for Gene Therapy, Houston
MD Anderson Cancer Center, Houston
Stanford University, Stanford
Fred Hutchinson Clinic, Seattle
Emory University, Atlanta
Dana Farber Cancer Institute, Boston
U-M Medical Center, Ann Arbor
Lead Sponsor
Blood and Marrow Transplant Clinical Trials Network
NETWORK
National Institutes of Health (NIH)
NIH
National Heart, Lung, and Blood Institute (NHLBI)
NIH
National Cancer Institute (NCI)
NIH
CSL Behring
INDUSTRY